Tim Stonehouse Joins U-Ploid as Head of Regulatory Affairs

OXFORD, February 10, 2026 — U-Ploid Biotechnologies, a venture-backed company developing next-generation reproductive health therapeutics, is pleased to announce the appointment of Tim Stonehouse as its first in-house Head of Regulatory Affairs. In this role, Tim will lead global regulatory strategy as the company advances its lead therapeutic programme, Lyvanta™, toward clinical evaluation.

Tim Stonehouse, Head of Regulatory Affairs at U-Ploid Biotechnologies, commented:

"I have spent my career navigating the complexities of bringing first-in-class modalities to market, from biologics to gene therapies. U-Ploid occupies a unique frontier in biotech, applying sophisticated molecular biology to the neglected space of reproductive longevity. The early data for Lyvanta™ is some of the most compelling I have seen in the sector, indicating that we can fundamentally change the success rate of assisted reproduction. My initial priority will be to further engage key regulators, such as FDA, EMA and MHRA, to build understanding and gain alignment on the most efficient development path for Lyvanta™.  I am thrilled to join the team as we work to bring this much-needed treatment to patients.

Lyvanta™, U-Ploid’s lead programme, is designed to address age-related decline in oocyte (egg) quality, a major biological contributor to IVF failure and miscarriage in women aged 35 and over. In pre-clinical mouse studies, Lyvanta™ has demonstrated an 84% reduction in age-related chromosomal errors (aneuploidy). U-Ploid’s approach focuses on improving the underlying biological quality of eggs, complementing existing fertility treatments that primarily address downstream selection.

Tim brings more than 25 years of international regulatory strategy experience across biotechnology and advanced therapies. He previously served as Vice President, International Regulatory Strategy at Vertex Pharmaceuticals and has held senior regulatory roles at Autolus, pioneering CAR-T therapies, and Celgene. Across his career, he has supported the development and approval of multiple complex therapeutic programmes across major global markets.

Jordan Abdi, Co-founder and CEO of U-Ploid Biotechnologies, added:

"Attracting a regulatory heavyweight of Tim’s calibre is a testament to the strength of our science. As we move into the clinic, Tim’s deep expertise in global strategy and his experience of leadership within the BIA will be instrumental. Shaping the regulatory path for novel interventions is critical at this stage, and Tim is the ideal person to lead us through this next phase of growth."

In addition to his industry roles, Tim served for four years as Chair of the Bioindustry Association (BIA) Regulatory Affairs Advisory Committee, where he was instrumental in shaping the UK’s post-Brexit life sciences regulatory landscape. At U-Ploid, he will work closely with the leadership team and external partners to support upcoming translational studies and global regulatory interactions.

About U-Ploid Biotechnologies

U-Ploid Biotechnologies is an Oxford-based biotechnology company dedicated to solving one of the world’s most pressing challenges in fertility: declining egg quality. U-Ploid is developing Lyvanta™, a novel therapeutic that targets the molecular pathways of oocyte ageing. By reducing chromosomal errors by over 80% in pre-clinical mouse models, U-Ploid aims to significantly increase the probability of healthy pregnancies for women in their mid-30s and beyond. For more information, go to u-ploid.com or follow us on LinkedIn.

Press and Investor Contact

press@u-ploid.com

‍